Lactic dehydrogenase (LDH) is an enzyme contained in cells. Whenever the cell integrity is compromised and the cell ruptures LDH is released and enters the bloodstream. If enough cells rupture an elevated LDH level results. The fact that ganetespib use lowers LDH levels is indicative of it's activity in preventing HIF-1alpha from invading and destroying cells. Proof of this protective mechanism by ganetespib will bode well for SNTA. This news coupled with improvements in progression free survival (PFS) as well as overall survival (OS) is great news indeed. It will be interesting to hear the details of the PFS and OS results particularly in breast cancer patients.